National Institute of Infectious Diseases: Peer-Reviewed Report on Moderna COVID-19 Vaccine Publishes
December 31, 2020
December 31, 2020
WASHINGTON, Dec. 31 (TNSJou) -- The U.S. Department of Health and Human Services' National Institute of Allergy and Infectious Diseases issued the following news release:
The investigational vaccine known as mRNA-1273 was 94.1% efficacious in preventing symptomatic coronavirus disease 2019 (COVID-19), according to preliminary results from a Phase 3 clinical trial reported in the New England Journal of Medicine. The vaccine also demonstrated efficacy in preventing severe COVID-1 . . .
The investigational vaccine known as mRNA-1273 was 94.1% efficacious in preventing symptomatic coronavirus disease 2019 (COVID-19), according to preliminary results from a Phase 3 clinical trial reported in the New England Journal of Medicine. The vaccine also demonstrated efficacy in preventing severe COVID-1 . . .